Shannon Thyme Klinger - 01 Mar 2023 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Chief Legal Officer
Signature: /s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol: MRNA
Transactions as of: 01 Mar 2023
Transactions value $: -$62,623
Form type: 4
Date filed: 03 Mar 2023, 15:21
Previous filing: 02 Mar 2023
Next filing: 09 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Options Exercise	$0	+930	+19.49%	$0.00	5.7K	01 Mar 2023	Direct	F1
transaction	MRNA	Common Stock	Sale	-$62.6K	-459	-8.05%	$136.43	5.24K	02 Mar 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRNA	Restricted Stock Units	Options Exercise	$0	-930	-24.99%	$0.00	2.79K	01 Mar 2023	Common Stock	930	$0.00	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units convert into common stock on a one-for-one basis.
F2	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3	25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.